SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-276676
Filing Date
2023-11-14
Accepted
2023-11-14 08:01:29
Documents
13
Period of Report
2023-11-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d437259d8k.htm   iXBRL 8-K 24339
2 EX-99.1 d437259dex991.htm EX-99.1 82509
  Complete submission text file 0001193125-23-276676.txt   244180

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA urgn-20231114.xsd EX-101.SCH 2849
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE urgn-20231114_lab.xml EX-101.LAB 17996
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE urgn-20231114_pre.xml EX-101.PRE 11261
7 EXTRACTED XBRL INSTANCE DOCUMENT d437259d8k_htm.xml XML 3362
Mailing Address 9 HA'TA'ASIYA ST RA'ANANA L3 4365007
Business Address 9 HA'TA'ASIYA ST RA'ANANA L3 4365007 972 9 770 7601
UroGen Pharma Ltd. (Filer) CIK: 0001668243 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38079 | Film No.: 231401662
SIC: 2834 Pharmaceutical Preparations